Alnylam Pharmaceuticals, Inc. (ALNY): יחס מחיר למכירות

Alnylam Pharmaceuticals relies on inelastic demand driven by its unique therapies for rare pathologies. The company's normalized P/S on GURU.Markets reflects market expectations, where 4.40 represents the current metric level. Professional management ensures transparency in the development of RNA interference and strives for full self-sufficiency. Modern biotechnological capacities are operating stably while undergoing scheduled line modernizations.

The P/S ratio relates a business's market capitalization to its annual revenue, allowing an investor to determine the premium paid per unit of sales. The current value of 4.40, represented by the price-to-sales ratio, reflects the premium for Alnylam Pharmaceuticals (ALNY) patent monopoly in the field of RNA interference, confirming the fundamental stability of the company's high margins and leadership in the rare disease market.